What is Electromedical Technologies?
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. operates as a commercial-stage manufacturer specializing in bioelectronic medical devices. The company is primarily focused on addressing chronic, acute, and post-operative pain through advanced electro-modulation techniques. Beyond its current product portfolio, the firm maintains active university collaboration agreements to pioneer research into the effects of electrical fields on cell signaling, virus assembly, and immune system modulation. This dual focus on immediate clinical application and long-term scientific discovery establishes Electromedical Technologies as a key player in the intersection of medical device engineering and therapeutic innovation.
How much funding has Electromedical Technologies raised?
Electromedical Technologies has raised a total of $2M across 2 funding rounds:
Other Financing Round
$1M
Private Equity
$1M
Other Financing Round (2020): $1M, investors not publicly disclosed
Private Equity (2021): $1M led by Yorkville Advisors Global
Key Investors in Electromedical Technologies
Yorkville Advisors Global
A private investment firm that provides growth capital and strategic financial solutions to small and mid-cap companies across various sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Electromedical Technologies?
With the recent influx of capital, Electromedical Technologies is poised to transition into a more aggressive growth phase. The strategic roadmap likely involves scaling manufacturing capabilities to meet rising demand for its FDA-cleared pain relief systems while simultaneously deepening its research pipeline. By prioritizing the development of electro-modulation protocols, the company aims to solidify its market position as a leader in non-pharmacological pain management. Future milestones will likely center on expanding clinical indications and leveraging data from ongoing research programs to enhance the efficacy of its bioelectronic platforms, ultimately driving long-term value for stakeholders and improving patient outcomes in the chronic pain landscape.
See full Electromedical Technologies company page
